SNAP Trial Celebrates One Year!
We have another important milestone to celebrate! On the 17th of February 2023, the SNAP (Staphylococcus Aureus Network Adaptive Platform) Trial reached its one-year anniversary.
In the last 12 months, the trial has successfully recruited more than 450 participants into the study, making it the second-largest clinical trial for Staphylococcus Aureus bloodstream infections in the world.
This is an adaptive platform clinical trial that aims to improve treatments for those with bloodstream infections of Staphylococcus Aureus or Golden Staph. It is a disease frequently seen by infectious diseases doctors and is one of the most common causes of bloodstream infections in the world. The SNAP trial looks at several different treatment strategies for these infections with the aim of improving outcomes for those affected by them.
In 2019, one million deaths were associated with Staph aureus infections. It was the leading bacterial cause of death in 135 countries and was associated with the most deaths in individuals older than 15 years, globally.
Spiral has been involved with the SNAP Trial since its inception. Josh Davis, SNAP's co-primary investigator, had worked with Spiral on previous studies, CAMERA 2 and ASCOT. Through Camera 2 they formed ‘a great relationship with Spiral’, acknowledging that the front end of the database was easy to use for sites.
Co-ordinating SNAP Trial Investigator, Professor Steven Tong says it was essential that the collection of data was done as smoothly as possible.
Adaptive Platform Trials are relatively new within the industry meaning that any APT requires complex bespoke database design, something that Professor Tong confrims Spiral provides with ease. It is a carefully considered process that requires collaboration between all parties involved.
Thanks to trials like SNAP, the current pool of evidence on how to best treat Staphylococcus Aureus continues to grow. It is a source of invaluable information that Spiral is proud to contribute to.
We’re looking forward to watching the SNAP trial develop further and are excited to see what crucial insights it provides in the treatment of this disease and the impact it has on human lives globally.
Read more on Spiral’s involvement with the SNAP Trial here.
